Managing Complexity in a Small Biotech: Integrating Multiple Programs, Modalities, Isotopes & CDMOs into One CMC Operating Model

• Explore how a small biotech can integrate multiple biologic modalities, isotopes, CDMOs, and clinical programs through a unified CMC and supply-chain operating model.
• Discuss why the greatest development risks often occur at the interfaces between biologics manufacturing, conjugation, radiolabeling, analytical testing, and clinical supply—and how clear ownership and governance can reduce those risks.
• Share practical lessons from technology transfer and conjugate comparability, including how material and process variability can affect downstream radiolabeling performance.

Speakers: